EluPro™ Named as 2025 Edison Award Winner

Rhea-AI Summary

Elutia (Nasdaq: ELUT) has received a 2025 Bronze Edison Award for their groundbreaking product EluPro™, the first FDA-cleared antibiotic-eluting bioenvelope. The innovation was recognized in the Post-Surgical Recovery Solutions category.

Launched in January 2025, EluPro combines a regenerative biomatrix with rifampin and minocycline antibiotics, designed to protect patients with cardiac implanted electronic devices (CIEDs) and neurostimulation devices. The technology addresses critical needs in the medical device industry, where approximately 600,000 CIEDs are implanted annually in the U.S., with complications occurring in 5-7% of cases.

The award selection process involved rigorous evaluation by the Edison Awards Steering Committee and independent experts, considering concept, value, delivery, and impact. The award ceremony took place on April 3, 2025, at the Luminary Hotel and Caloosa Sound Convention Center in Fort Myers, Florida.

Innovative Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Pacemakers and Neurostimulators Earns Bronze in Post-Surgical Recovery Solutions Category

SILVER SPRING, Md., April 04, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that EluPro™, the first ever FDA-cleared antibiotic-eluting bioenvelope was honored with a 2025 Bronze Edison Award™ for its innovative approach to reducing post-surgical complications. The 2025 finalists were selected from thousands of submissions, rigorously evaluated on concept, value, delivery, and impact. The selection process was led by the Edison Awards Steering Committee and an independent panel of experts, including scientists, engineers, designers, and business leaders.

“It’s an incredible honor to accept this award on behalf of Elutia and to see EluPro recognized alongside some of the most innovative products in the world,” said Dr. Randy Mills, CEO of Elutia. “This isn’t just a prestigious award—it’s a reflection of our team’s ridiculously relentless commitment to solving real problems for real people. I’m proud of the Elutia CRU for pushing boundaries every day so patients everywhere can thrive without compromise. Congratulations to the entire team!”

Launched in January 2025, EluPro is cleared for use across all major cardiac implanted electronic device (CIED) products including pacemakers and implantable defibrillators, as well as for neurostimulation devices. Unlike synthetic alternatives, EluPro combines a soft, regenerative biomatrix with the trusted antibiotics rifampin and minocycline to address CIED complications and support healthy healing. With more than 600,000 CIEDs implanted annually in the U.S. and complications—such as infection, migration, and skin erosion—occurring in up to 5-7% of cases, the need for improved outcomes is clear. EluPro provides a comprehensive solution for both patients and clinicians.

The 2025 Edison Awards were presented on Thursday, April 3 at the Luminary Hotel and the Caloosa Sound Convention Center in Fort Myers, Florida.

To learn more, visit www.elutia.com/products/elupro/.

About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.

About the Edison Awards™
Established in 1987, the Edison Awards are dedicated to recognizing, honoring and fostering innovations and innovators. Named after Thomas Alva Edison (1847-1931), the annual competition honors excellence in new product and service development, marketing, design and innovation. For more information visit www.edisonawards.com.

Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. Forward-looking statements contained in this press release include, without limitation, any statements we make regarding the potential for EluPro to represent a meaningful step forward in CIED antibiotic envelope technology. These forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to us. Such beliefs and assumptions may or may not prove to be correct. Additionally, such forward-looking statements are subject to a number of known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied in the forward-looking statements, including, but not limited to the following: the risk that clinical research data may not match preclinical study data; our ability to successfully commercialize, market and sell our EluPro product; our ability to continue as a going concern; our ability to achieve or sustain profitability; the risk of product liability claims and our ability to obtain or maintain adequate product liability insurance; our ability to defend against the various lawsuits and claims related to our recalled FiberCel and other viable bone matrix products and avoid a material adverse financial consequence from those lawsuits and claims; our ability to prevail in lawsuits and claims seeking indemnity, contribution and insurance coverage for FiberCel and other viable bone matrix product liabilities; the continued and future acceptance of our products by the medical community; our ability to enhance our products, expand our product indications and develop, acquire and commercialize additional product offerings; our dependence on our commercial partners and independent sales agents to generate a substantial portion of our net sales; our dependence on a limited number of third-party suppliers and manufacturers, which, in certain cases are exclusive suppliers for products essential to our business; our ability to successfully realize the anticipated benefits of the sale of our Orthobiologics business; physician awareness of the distinctive characteristics, benefits, safety, clinical efficacy and cost-effectiveness of our products; our ability to compete against other companies, most of which have longer operating histories, more established products and/or greater resources than we do; pricing pressure as a result of cost-containment efforts of our customers, purchasing groups, third-party payors and governmental organizations could adversely affect our sales and profitability; our ability to obtain regulatory approval or other marketing authorizations by the FDA and comparable foreign authorities for our products and product candidates; our ability to obtain, maintain and adequately protect our intellectual property rights; and other important factors which can be found in the “Risk Factors” section of Elutia’s public filings with the Securities and Exchange Commission (“SEC”), including Elutia’s Annual Report on Form 10-K for the year ended December 31, 2024, as such factors may be updated from time to time in Elutia’s other filings with the SEC, accessible on the SEC’s website at www.sec.gov and the Investor Relations page of Elutia’s website at https://investors.elutia.com. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. Any forward-looking statement made by Elutia in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, Elutia expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investors:
Matt Steinberg
FINN Partners
matt.steinberg@finnpartners.com

This press release was published by a CLEAR® Verified individual.

FAQ

What makes EluPro unique in preventing CIED complications?

EluPro is the first FDA-cleared antibiotic-eluting bioenvelope that combines a soft regenerative biomatrix with rifampin and minocycline antibiotics, specifically designed to prevent complications in cardiac device implants.

How many patients could potentially benefit from Elutia's EluPro technology annually?

With 600,000 cardiac implanted electronic devices (CIEDs) performed annually in the U.S., and a 5-7% complication rate, approximately 30,000-42,000 patients could benefit from EluPro's protection.

When did Elutia (ELUT) launch EluPro and what devices is it cleared for?

Elutia launched EluPro in January 2025, with FDA clearance for use with all major cardiac implanted electronic devices, including pacemakers, implantable defibrillators, and neurostimulation devices.

What recognition did Elutia's EluPro receive at the 2025 Edison Awards?

EluPro received the Bronze Edison Award in the Post-Surgical Recovery Solutions category, selected from thousands of submissions after evaluation by industry experts.

What specific complications does Elutia's EluPro aim to prevent in CIED patients?

EluPro is designed to address complications such as infection, migration, and skin erosion, which occur in 5-7% of CIED implant cases.